Barron Associates Receives Grant to Develop Smart Sensors for Cystic Fibrosis Treatments

Barron Associates has received a grant from the National Heart, Lung, and Blood Institute for the development of sensors that objectively monitor the duration and pattern of adherence to CF airway clearance and inhaled medication therapies. This Phase I SBIR research effort will provide accurate assessment of patient adherence to CF treatments as a tool to ease the burden of managing a complex treatment regimen, thereby promoting adherence to critical treatments that many patients neglect. The ultimate goal is to improve health outcomes and reduce the costs associated with expensive and preventable hospitalizations due to incorrect treatment usage.